North America Liver Cancer Diagnostics Market Forecast to 2028 – COVID-19 Impact and Analysis – by Type (Laboratory Tests, Endoscopy, Imaging, Biopsy, and Others) and End User (Hospitals and Diagnostic Laboratories, Academic and Research Institutes, and CRO Laboratories)
The liver cancer diagnostics market in North America is expected to grow from US$ 3,843.93 million in 2021 to US$ 6,666.24 million by 2028. It is estimated to grow at a CAGR of 8.2% from 2021 to 2028.
The ability to accurately diagnose liver cancer progression is critical for selecting the appropriate treatment option. Further, various companies and organizations have taken enormous initiatives to develop and implement innovative solutions for the early identification of this disease in response to the rising demand. For instance, in March 2020, Roche Holding AG's Elecsys GALAD score received the US Food and Drug Administration's breakthrough device status for the early detection of an advanced form of liver cancer. The Swiss drugmaker's calculator combines factors including age, gender, and biomarker results to detect early-stage hepatocellular carcinoma, which is the most common form of liver cancer. Further, Elecsys GALAD score is designed to support clinicians by providing them with a timely and accurate diagnosis of hepatocellular carcinoma.
The research and development (R&D) expenditure in 2021 was US$ 14.65 billion, and in 2020, it was US$ 13.17 billion. The research and development (R&D) expenditure grew by 14% on a core basis in F. Hoffmann-La Roche Ltd., mostly driven by late-stage investments in oncology, ophthalmology, and personalized healthcare. In 2021, the R&D investment in the diagnostic division was US$ 1,878.92 million. Similarly, In November 2019, EXACT Sciences Corporation received the Food and Drug Administration's (FDA) breakthrough designation for its blood-based test for early detection of liver cancer.
Additionally, in June 2020, National Institutes of Health (NIH) scientists developed blood tests to help improve liver cancer screening, led by researchers at the National Cancer Institute (NCI). In addition, in June 2019, CancerSEEK, a liquid biopsy test, was designed by researchers at Johns Hopkins University. The test was designed to diagnose multiple cancers, including stomach, liver, ovarian, and esophageal, at an early stage, facilitating early treatment. Therefore, the increasing R&D investments and development of diagnostic tests for the detection of liver cancer are driving the liver cancer diagnostics market.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America Liver cancer diagnostics market at a substantial CAGR during the forecast period.
North America Liver Cancer Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
Get more information on this report :
North America Liver Cancer Diagnostics Market Segmentation
The North America liver cancer diagnostics market is analyzed on the basis of type, end user, and country. Based on type, the market is segmented into laboratory tests, imaging, endoscopy, biopsy, and others. In 2021, the laboratory tests segment held the largest share of the market, and the imaging segment is expected to register a higher CAGR during the forecast period.
Based on laboratory tests, the market is segmented into blood tests and biomarkers. In 2021, the blood tests segment held a larger market share, and the same segment is expected to register the highest CAGR in the market during the forecast period.
Based on end user, the market is segmented into hospitals and diagnostic laboratories, academic and research institutes, and CRO laboratories. In 2021, the hospitals and diagnostic laboratories segment held the largest share of the market, and the same segment is expected to register a higher CAGR during the forecast period.
Based on country, the North America liver cancer diagnostics market is segmented into the US, Canada, and Mexico. In 2021, the US held the largest market share, and it is also expected to grow at the fastest CAGR during the forecast period.
Abbott; bioMerieux SA; F. HOFFMANN-LA ROCHE LTD.; Illumina, Inc.; Koninklijke Philips N.V.; QIAGEN; Siemens Healthineers AG; THERMO FISHER SCIENTIFIC INC.; GE Healthcare; Perspectum; and Helio, Inc. are the leading companies in the North America liver cancer diagnostics market.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Liver Cancer Diagnostics Market – By Type
1.3.2 North America Liver Cancer Diagnostics Market – By End User
1.3.3 North America Liver Cancer Diagnostics Market – By Country
2. North America Liver Cancer Diagnostics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Liver Cancer Diagnostics Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Experts Opinion
5. North America Liver Cancer Diagnostics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Liver Cancer
5.1.2 Strengthening R&D Investments for the Development of Novel Diagnostic Testing
5.2 Market Restraints
5.2.1 Higher Cost of Technologically Advanced Liver Cancer Diagnostic Solutions
5.3 Market Opportunities
5.3.1 Heighten Demand for Point-of-Care Testing
5.4 Future Trends
5.4.1 Prospering Emergence of New Technologies
5.5 Impact Analysis
6. North America Liver Cancer Diagnostics Market Analysis
6.1 North America Liver Cancer Diagnostics Market Revenue Forecast and Analysis
7. North America Liver Cancer Diagnostics Market Analysis – By Type
7.1 Overview
7.2 North America Liver Cancer Diagnostics Market Revenue Share, by Type (2021 and 2028)
7.3 Laboratory Tests
7.3.1 Overview
7.3.2 Laboratory Tests: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.1 Blood Tests
7.3.2.1.1 Overview
7.3.2.1.2 Blood Tests: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.2 Biomarkers
7.3.2.2.1 Overview
7.3.2.2.2 Biomarkers: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Endoscopy
7.4.1 Overview
7.4.2 Endoscopy: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Imaging
7.5.1 Overview
7.5.2 Imaging: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Biopsy
7.6.1 Overview
7.6.2 Biopsy: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8. North America Liver Cancer Diagnostics Market Analysis – By End User
8.1 Overview
8.2 North America Liver Cancer Diagnostics Market Revenue Share, By End User (2021 and 2028)
8.3 Hospitals and Diagnostics Laboratories
8.3.1 Overview
8.3.2 Hospitals and Diagnostics Laboratories: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Academic and Research Institutes
8.4.1 Overview
8.4.2 Academic and Research Institutes: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.5 CRO Laboratories
8.5.1 Overview
8.5.2 CRO Laboratories: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9. North America Liver Cancer Diagnostics Market – Country Analysis
9.1 Overview
9.1.1 North America: Liver Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
9.1.1.1 US: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.1.1 Overview
9.1.1.1.2 US: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.1.3 US Liver Cancer Diagnostics Market, by Type– Revenue and Forecast to 2028 (USD Million)
9.1.1.1.3.1 US Liver Cancer Diagnostics Market, by Laboratory Tests – Revenue and Forecast to 2028 (USD Million)
9.1.1.1.4 US Liver Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
9.1.1.2 Canada: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.2.1 Overview
9.1.1.2.2 Canada: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.2.3 Canada Liver Cancer Diagnostics Market, by Type– Revenue and Forecast to 2028 (USD Million)
9.1.1.2.3.1 Canada Liver Cancer Diagnostics Market, by Laboratory Tests – Revenue and Forecast to 2028 (USD Million)
9.1.1.2.4 Canada Liver Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
9.1.1.3 Mexico: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.3.1 Overview
9.1.1.3.2 Mexico: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
9.1.1.3.3 Mexico Liver Cancer Diagnostics Market, by Type– Revenue and Forecast to 2028 (USD Million)
9.1.1.3.3.1 Mexico Liver Cancer Diagnostics Market, by Laboratory Tests – Revenue and Forecast to 2028 (USD Million)
9.1.1.3.4 Mexico Liver Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
10. North America Liver Cancer Diagnostics Market– Industry Landscape
10.1 Overview
10.2 Organic Developments
10.2.1 Overview
10.3 Inorganic Developments
10.3.1 Overview
11. Company Profiles
11.1 Abbott
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 bioMerieux SA
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 F. HOFFMANN-LA ROCHE LTD.
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Illumina, Inc.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Koninklijke Philips N.V.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 QIAGEN
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Siemens Healthineers AG
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 THERMO FISHER SCIENTIFIC INC.
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 GE Healthcare
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Perspectum
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
11.11 Helio, Inc
11.11.1 Key Facts
11.11.2 Business Description
11.11.3 Products and Services
11.11.4 Financial Overview
11.11.5 SWOT Analysis
11.11.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
LIST OF TABLES
Table 1. US Liver Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 2. US Liver Cancer Diagnostics Market, by Laboratory Tests – Revenue and Forecast to 2028 (USD Million)
Table 3. US Liver Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 4. Canada Liver Cancer Diagnostics Market, by Type-Revenue and Forecast to 2028 (USD Million)
Table 5. Canada Liver Cancer Diagnostics Market, by Laboratory Tests – Revenue and Forecast to 2028 (USD Million)
Table 6. Canada Liver Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 7. Mexico Liver Cancer Diagnostics Market, by Type -Revenue and Forecast to 2028 (USD Million)
Table 8. Mexico Liver Cancer Diagnostics Market, by Laboratory Tests -Revenue and Forecast to 2028 (USD Million)
Table 9. Mexico Liver Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 10. Organic Developments in the Liver Cancer Diagnostics Market
Table 11. Inorganic Developments in the Liver Cancer Diagnostics Market
Table 12. Glossary of Terms
LIST OF FIGURES
Figure 1. North America Liver Cancer Diagnostics Market Segmentation
Figure 2. North America Liver Cancer Diagnostics Market Segmentation, By Country
Figure 3. North America Liver Cancer Diagnostics Market Overview
Figure 4. Laboratory Tests Segment Held Largest Share by Type in North America Liver Cancer Diagnostics Market
Figure 5. The US Is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. North America Liver Cancer Diagnostics Market, Industry Landscape
Figure 7. North America: PEST Analysis
Figure 8. Experts Opinion
Figure 9. Impact Analysis of Drivers and Restraint Pertaining to North America Liver Cancer Diagnostics Market
Figure 10. North America Liver Cancer Diagnostics Market – Revenue Forecast and Analysis – 2021- 2028
Figure 11. North America Liver Cancer Diagnostics Market Revenue Share, by Type (2021 and 2028)
Figure 12. Laboratory Tests: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Blood Tests: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Biomarkers: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Endoscopy: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Imaging: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Biopsy: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Others: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. North America Liver Cancer Diagnostics Market Revenue Share, By End User (2021 and 2028)
Figure 20. Hospitals and Diagnostics Laboratories: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Academic and Research Institutes: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. CRO Laboratories: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. North America: Liver Cancer Diagnostics Market, by Key Country – Revenue (2021) (USD Million)
Figure 24. North America: Liver Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
Figure 25. US: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 26. Canada: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 27. Mexico: Liver Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
- Abbott
- bioMerieux SA
- F. HOFFMANN-LA ROCHE LTD.
- Illumina, Inc.
- Koninklijke Philips N.V.
- QIAGEN
- Siemens Healthineers AG
- THERMO FISHER SCIENTIFIC INC.
- GE Healthcare
- Perspectum
- Helio, Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America liver cancer diagnostics market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the North America liver cancer diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the liver cancer diagnostics market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution